Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP (2022) The second decade of anti-TNF-α therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int 42(9):1493–1511. https://doi.org/10.1007/s00296-022-05136-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ntusi NAB, Francis JM, Sever E, Liu A, Piechnik SK, Ferreira VM, Matthews PM, Robson MD, Wordsworth PB, Neubauer S, Karamitsos TD (2018) Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. Int J Cardiol 270:253–259

Article  PubMed  Google Scholar 

Toufaily A (2020) Severe cardiomyopathy induced by Adalimumab administration for Crohn’s disease. J Cardio Case Rep 3. https://doi.org/10.15761/JCCR.1000129

Grillo TG, Silveira CFDSMP, Quaglio AEV, Dutra RM, Baima JP, Bazan SGZ, Sassaki L (2023) Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature. World J Cardiol 15(5):217–228. https://doi.org/10.4330/wjc.v15.i5.217

Article  PubMed  PubMed Central  Google Scholar 

Coulson EJ, Ng WF, Goff I, Foster HE (2013) Cardiovascular risk in juvenile idiopathic arthritis. Rheumatology (Oxford) 52(7):1163–1171. https://doi.org/10.1093/rheumatology/ket106

Article  CAS  PubMed  Google Scholar 

Page RL 2nd, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, American heart association clinical pharmacology and heart failure and transplantation committees of the council on clinical cardiology; council on cardiovascular surgery and anesthesia; council on cardiovascular and stroke nursing; and council on quality of care and outcomes research (2016) Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 134(6):e32-69. https://doi.org/10.1161/CIR.0000000000000426. Erratum in: Circulation. 2016;134(12):e261. https://doi.org/10.1161/CIR.0000000000000449

Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, Colbert RA, Feldman BM, Ferguson PJ, Gewanter H, Guzman J, Horonjeff J, Nigrovic PA, Ombrello MJ, Passo MH, Stoll ML, Rabinovich CE, Schneider R, Halyabar O, Hays K, Shah AA, Sullivan N, Szymanski AM, Turgunbaev M, Turner A, Reston J (2019) 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol 71(6):846–863. https://doi.org/10.1002/art.40884

Article  PubMed  PubMed Central  Google Scholar 

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3

Article  PubMed  Google Scholar 

Atzeni F, Nucera V, Galloway J, Zoltán S, Nurmohamed M (2020) Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. Expert Opin Biol Ther 20(5):517–524. https://doi.org/10.1080/14712598.2020.1704727

Article  CAS  PubMed  Google Scholar 

Gruca M, Orczyk K, Zamojska J, Niewiadomska-Jarosik K, Stańczyk J, Smolewska E (2023) Why and how should we assess the cardiovascular risk in patients with juvenile idiopathic arthritis? A single-centre experience with carotid intima-media measurements. Child (Basel) 10(3):422. https://doi.org/10.3390/children10030422

Article  Google Scholar 

Schumacher SM, Naga Prasad SV (2018) Tumor necrosis factor-α in heart failure: an updated review. Curr Cardiol Rep 20(11):117. https://doi.org/10.1007/s11886-018-1067-7

Article  PubMed  PubMed Central  Google Scholar 

Sinagra E, Perricone G, Romano C, Cottone M (2013) Heart failure and anti-tumor necrosis factor-alpha in systemic chronic inflammatory diseases. Eur J Intern Med 24(5):385–392. https://doi.org/10.1016/j.ejim.2012.12.015

Article  CAS  PubMed  Google Scholar 

Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138(10):807–811. https://doi.org/10.7326/0003-4819-138-10-200305200-00008

Article  PubMed  Google Scholar 

Castro Rocha FA, Silva FS Jr (2010) Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis. J Clin Rheumatol 16(2):81–82. https://doi.org/10.1097/RHU.0b013e3181d06f5b

Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116(5):305–311. https://doi.org/10.1016/j.amjmed.2003.09.039

Article  PubMed  Google Scholar 

Kotyla PJ (2018) Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? Int J Mol Sci 19(6):1739. https://doi.org/10.3390/ijms19061739

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cole J, Busti A, Kazi S (2007) The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 27(4):369–373. https://doi.org/10.1007/s00296-006-0215-3

Article  CAS  PubMed  Google Scholar 

Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, Kerr DR, Tsuji W, Baumgartner SW (2007) A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) 46(7):1122–1125. https://doi.org/10.1093/rheumatology/kem033

Article  CAS  PubMed  Google Scholar 

Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, ARTIS Group (2005) Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 64(2):246–252. https://doi.org/10.1136/ard.2004.023473

Article  CAS  PubMed  Google Scholar 

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272–2283. https://doi.org/10.1002/art.24638

Article  CAS  PubMed  Google Scholar 

Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837–846. https://doi.org/10.1111/j.1749-6632.2009.04621.x

Article  CAS  PubMed  Google Scholar 

Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM (2017) Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol 31(1):89–95. https://doi.org/10.1111/jdv.13746

Article  CAS  PubMed  Google Scholar 

Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71(11):1788–1800. https://doi.org/10.1002/art.41032

Article  CAS  PubMed  Google Scholar 

Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, Swierkot J, Khan N, Bu X, Li Y, Song IH (2022) Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open 8(1). https://doi.org/10.1136/rmdopen-2021-002012

Blair HA, Secukinumab (2019) A review in ankylosing spondylitis. Drugs 79(4):433–443

Article  CAS  PubMed  PubMed Central  Google Scholar 

von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T (2019) Impact of Secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 139(5):1054–1062

Article  Google Scholar 

Makavos G, Ikonomidis I, Andreadou I, Varoudi M, Kapniari I, Loukeri E, Theodoropoulos K, Pavlidis G, Triantafyllidi H, Thymis J, Parissis J, Tsoumani M, Rafouli-Stergiou P, Katsimbri P, Papadavid E (2020) Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis. Can J Cardiol 36(1):100–111. https://doi.org/10.1016/j.cjca.2019.06.021

Article  PubMed  Google Scholar 

Xie F, Yun H, Levitan EB, Muntner P, Curtis JR (2019) Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 71(8):1004–1018. https://doi.org/10.1002/acr.23737

Article  CAS  PubMed  Google Scholar 

Wooten MD, Reddy GV, Johnson RD (2000) Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J 72(12):517–519

CAS  PubMed  Google Scholar